The Implications of the High Rate of Dose Holds in a Dose Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Pharmacy Times® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

In this video, Trudel discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Related Content:

ConferenceHematologyRetailOncology
When to Call, When to Counsel: Serotonin Syndrome
Esophageal Cancer Rates Nearly Double in Adults 45 to 64 Over 7 Years
Erenumab Is Well Tolerated for up to 12 Months, Study Results Show